Lv6
1624 积分 2025-08-24 加入
D1 Agonist Improved Movement of Parkinsonian Nonhuman Primates with Limited Dyskinesia Side Effects
15天前
已完结
Cyclic Peptide Therapeutic Agents Discovery: Computational and Artificial Intelligence-Driven Strategies
22天前
已完结
The coming of age of cyclic peptide drugs: an update on discovery technologies
22天前
已完结
Series of Novel and Highly Potent Cyclic Peptide PCSK9 Inhibitors Derived from an mRNA Display Screen and Optimized via Structure-Based Design
22天前
已完结
Discovery Process of Enlicitide, a Highly Engineered Macrocyclic Peptide Therapeutic, through Issue-Driven Fragment-Based Synthetic Assembly and SAR
22天前
已完结
A Series of Novel, Highly Potent, and Orally Bioavailable Next-Generation Tricyclic Peptide PCSK9 Inhibitors
22天前
已完结
Development of Orally Bioavailable Peptides Targeting an Intracellular Protein: From a Hit to a Clinical KRAS Inhibitor
23天前
已完结
Exploiting Bridged Conformations for Precise Molecular Recognition in the Design of KRAS-Selective, Orally Available Macrocyclic Peptides
23天前
已完结
LUNA18, a macrocyclic orally bioavailable peptide pan-RAS inhibitor, discovered from a beyond rule of 5 drug discovery platform
23天前
已完结
Derivatization with fatty acids in peptide and protein drug discovery
28天前
已完结